GlassScriptPhysician profile
William Seely
NPI 1609163880
$8,587.61
in general payments reported to CMS, 2019-2025
30 companies · $940 in 2025
The $940 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $175 · 2021: $2,124 · 2022: $370 · 2023: $1,673 · 2024: $2,838 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,012 · Travel and Lodging: $2,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,012.35 |
| Travel and Lodging | $2,437.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,437.19 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, Superion Indirect Decompression System |
| Nalu Medical, INC. | $1,000.96 | 2021-2023 | Nalu Neurostimulation System |
| Abbott Laboratories | $631.30 | 2023-2024 | Proclaim, Eterna, Prodigy |
| Spr Therapeutics, INC | $410.55 | 2025 | Sprint Pns System |
| Medtronic, INC. | $155.44 | 2023-2024 | Intellis Adaptivestim, Synchromedii, Accurian |
| Vertos Medical, INC. | $126.41 | 2023-2024 | Mild Device Kit |
| Flowonix Medical Incorporated | $105.50 | 2019 | |
| Foundation Fusion Solutions, LLC | $100.86 | 2024 | |
| Collegium Pharmaceutical, INC. | $73.28 | 2020-2023 | Belbuca |
| Innovation Technologies INC | $55.77 | 2025 | Irrisept |
| Gentleman Orthopedic Solutions | $51.14 | 2019 | |
| Painteq LLC | $40.06 | 2022-2023 | Painteq |
| Vertiflex, INC. | $38.68 | 2019 | |
| Amgen INC. | $36.82 | 2020-2021 | |
| Lilly USA, LLC | $34.41 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $33.40 | 2019-2021 | |
| Relievant Medsystems, INC. | $27.50 | 2023 | Intracept |
| Biodelivery Sciences International, INC. | $23.60 | 2020 | |
| Bioventus LLC | $23.44 | 2025 | Xcell |
| Pacira Pharmaceuticals Incorporated | $23.03 | 2025 | Iovera, Zilretta |
| Nevro Corp. | $20.22 | 2019 | |
| Abbvie INC. | $19.89 | 2024 | |
| Tersera Therapeutics LLC | $16.84 | 2020 | |
| Saluda Medical Americas, INC. | $16.39 | 2025 | Evoke |
| Sunovion Pharmaceuticals INC. | $16.26 | 2019 | |
| Assertio Therapeutics, INC. | $15.62 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.36 | 2024 | Relistor |
| Scilex Pharmaceuticals INC. | $14.13 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.33 | 2019 | |
| Heraeus Medical, LLC. | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Seely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.